DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors
02 Aprile 2021 - 10:30PM
DBV Technologies Announces Appointment of Timothy E. Morris to
Board of Directors
Montrouge, France, April 2, 2021DBV
Technologies Announces Appointment of Timothy E. Morris to Board of
Directors
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, announced today the provisional
appointment of Mr. Timothy E. Morris, as director, by the DBV Board
of Directors, effective March 30, 2021. Mr. Morris will serve as a
member of the Audit Committee of the Board. With this addition, the
Board comprises nine directors.
“We are pleased to welcome Tim Morris as a new
director to the DBV Board,” said Michel de Rosen, Chairman of DBV
Technologies’ Board of Directors. “Tim brings to DBV more than 20
years of leadership experience in the biopharma sector and he is
highly regarded for his finance and commercial capabilities. We
believe he will add tremendous value to our Board and DBV as a
whole.”
Mr. Morris has been the Chief Operating Officer
and Chief Financial Officer of Humanigen, Inc. since August 2020.
Prior to joining Humanigen’s management team, Mr. Morris served as
Chair of the Company’s Audit Committee. Mr. Morris has spent
more than two decades leading the financial, commercial, and
manufacturing functions at several public biopharmaceutical
companies, including Iovance, AcelRx, VIVUS, and Questcor (formerly
Ribogene). Mr. Morris received his Bachelor of Science in Business
with an emphasis in Accounting from California State University,
Chico, and is a Certified Public Accountant (Inactive).
“The current state of DBV’s European and U.S.
regulatory progress and pipeline potential make it an exciting time
to join the company,” said Timothy Morris. “I am honored to join
DBV and look forward to serving as a member of the Board and Audit
Committee and contributing to the success of the Company.”
Mr. Morris’ appointment is subject to
ratification and will be submitted to a shareholder vote at the
Ordinary and Extraordinary General Meeting that DBV Technologies
will convene on May 19, 2021.
About DBV Technologies DBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV Technologies’ method of delivering biologically active
compounds to the immune system through intact skin. With this new
class of non-invasive product candidates, the Company is dedicated
to safely transforming the care of food allergic patients. DBV
Technologies’ food allergies programs include ongoing clinical
trials of Viaskin Peanut. DBV Technologies has global headquarters
in Montrouge, France and offices in Bagneux, France, and North
American operations in Summit, NJ and New York, NY. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345), part of the SBF120 index, and the
Company’s ADSs (each representing one-half of one ordinary share)
are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Forward-Looking StatementsThis
press release may contain forward-looking statements, including
statements regarding Company’s anticipated Ordinary and
Extraordinary General Meeting of Shareholders, DBV’s regulatory
progress, and the potential of DBV’s pipeline. These
forward-looking statements and estimates are not promises or
guarantees and involve substantial risks and uncertainties. Among
the factors that could cause actual occurrences to differ
materially from those described or projected herein include
uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals and
those associated with scheduling and holding public events,
including the impact of the COVID-19 pandemic A further
discussion of risks and uncertainties that could cause actual
results to differ materially from those set forth in the
forward-looking statements in this press release can be found in
DBV Technologies’ regulatory filings with the French Autorité des
Marchés Financiers, DBV Technologies’ filings and reports with the
U.S. Securities and Exchange Commission, including in DBV
Technologies’ Annual Report on Form 10-K for the year ended
December 31, 2020, and future filings and reports by DBV
Technologies. Existing and prospective investors are cautioned not
to place undue reliance on these forward-looking statements and
estimates, which speak only as of the date hereof. Other than as
required by applicable law, DBV Technologies undertakes no
obligation to update or revise the information contained in this
Press Release.
Investor Contact Anne PollakDBV
Technologies+1 857-529-2363anne.pollak@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com
Grafico Azioni DBV Technologies (EU:DBV)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni DBV Technologies (EU:DBV)
Storico
Da Apr 2023 a Apr 2024